Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth

D Roberts1, S Dalziel

  • 1Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool, Merseyside, UK L8 7SS. devender.roberts@lwh.nhs.uk

Insights

Antenatal corticosteroids significantly reduce neonatal death and respiratory distress syndrome (RDS) in preterm infants. This treatment is recommended for women at risk of preterm birth to improve fetal lung maturation.

Area of Science:

  • Perinatal Medicine
  • Neonatology
  • Obstetrics

Background:

  • Respiratory distress syndrome (RDS) is a major cause of mortality and disability in preterm infants.
  • Antenatal corticosteroid administration is a key intervention to mitigate RDS.

Purpose of the Study:

  • To evaluate the impact of antenatal corticosteroids on fetal and neonatal outcomes.
  • To assess effects on maternal health and long-term child development.

Main Methods:

  • Systematic review of randomized controlled trials comparing antenatal corticosteroids with placebo or no treatment.
  • Data extraction and quality assessment by two independent reviewers.

Main Results:

  • Antenatal corticosteroids reduced neonatal death (RR 0.69) and RDS (RR 0.66).
  • Significant reductions observed in cerebroventricular hemorrhage, necrotizing enterocolitis, and systemic infections.
  • No increased risk of maternal mortality or chorioamnionitis.

Conclusions:

  • Evidence supports routine use of a single course of antenatal corticosteroids for women at risk of preterm birth.
  • Further research needed on optimal dosing, corticosteroid choice, multiple pregnancies, and long-term effects.
Abstract

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...